Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML

Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML

(1) Background: High-dose chemotherapy (HDCT) before autologous stem cell transplantation (ASCT) in acute myeloid leukemia (AML) patients predominantly combines busulfan with cyclophosphamide or melphalan. Treosulfan compares favorably regarding lower inter-individual bioavailability and neurotoxici...

Full description

Bibliographic Details
Main Authors: Ekaterina Gurevich, Michael Hayoz, Yolanda Aebi, Carlo R. Largiadèr, Behrouz Mansouri Taleghani, Ulrike Bacher, Thomas Pabst
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
acute myeloid leukemia (AML)
autologous stem cell transplantation (ASCT)
high-dose chemotherapy (HDCT)
treosulfan
biovariability
pharmacologic monitoring
Online Access:https://www.mdpi.com/2072-6694/14/4/1024

Internet

https://www.mdpi.com/2072-6694/14/4/1024

Similar Items